NICE recommends Bayer’s Nubeqa® (darolutamide) plus androgen deprivation therapy as a treatment option for patients with hormone-sensitive metastatic prostate cancer Nubeqa® (darolutamide) plus ...

Phase 3 ARENSENS clinical trial results were presented at JADPRO 2025, indicating darolutamide plus ADT improved rPFS in prostate cancer.

Enzalutamide plus leuprolide reduces the risk of death by more than 40% in biochemically recurrent prostate cancer compared to leuprolide alone.

The American Cancer Society tracks survival rates for 22 types of localized cancer, including the most common in the US: prostate (100%), skin (99.6% five-year survival rate), breast (99.3%), lung (65 ...

A new phase 3 trial reveals that combining enzalutamide and leuprolide significantly improves overall survival for men with ...

Targeting prostate-specific membrane antigen, Lu-PSMA-617 has demonstrated clinical benefits in patients with PSMA-positive ...

BERLIN — For men with high-risk biochemically recurrent prostate cancer, adding enzalutamide (Xtandi) to standard androgen ...

Combining 177 Lu-PSMA-617 with SOC produced statistically significant rPFS, reducing the risk of radiographic progression or death by 28% (HR 0.72; 95% CI, 0.58-0.90) vs SOC alone in patients with ...

A targeted drug combination delays advanced prostate cancer in men with specific DNA repair gene mutations. A large international study led by researchers at UCL has found that a new combination of dr ...

The 2025 ESMO annual meeting featured a metastatic castration-resistant prostate cancer (mCRPC) session and a presentation by ...

A new drug combination to treat advanced recurring prostate cancer has shown remarkable results in a long-term trial, ...

Adding apalutamide (Erleada) to androgen deprivation therapy (ADT) in patients with biochemically recurrent prostate cancer reduced the risk of developing metastases and castration-resistant disease, ...